These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

421 related articles for article (PubMed ID: 7622824)

  • 21. Selective serotonin reuptake inhibitors in the treatment of paediatric anxiety disorders: a review.
    Murphy TK; Bengtson MA; Tan JY; Carbonell E; Levin GM
    Int Clin Psychopharmacol; 2000 Aug; 15 Suppl 2():S47-63. PubMed ID: 11110019
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A review of the efficacy of selective serotonin reuptake inhibitors in obsessive-compulsive disorder.
    Pigott TA; Seay SM
    J Clin Psychiatry; 1999 Feb; 60(2):101-6. PubMed ID: 10084636
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacologic management of obsessive-compulsive disorder.
    Jackson CW; Morton WA; Lydiard RB
    South Med J; 1994 Mar; 87(3):310-21. PubMed ID: 8134850
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Fluvoxamine: a review of its therapeutic potential in the management of anxiety disorders in children and adolescents.
    Cheer SM; Figgitt DP
    Paediatr Drugs; 2001; 3(10):763-81. PubMed ID: 11706925
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Serotonergic compounds in panic disorder, obsessive-compulsive disorder and anxious depression: A concise review.
    Den Boer JA; Westenberg HGM
    Hum Psychopharmacol; 1995 Oct; 10 Suppl 3(S3):S173-S183. PubMed ID: 29569409
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Augmentation with fluvoxamine but not maprotiline improves negative symptoms in treated schizophrenia: evidence for a specific serotonergic effect from a double-blind study.
    Silver H; Shmugliakov N
    J Clin Psychopharmacol; 1998 Jun; 18(3):208-11. PubMed ID: 9617979
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Fluvoxamine in the treatment of obsessive-compulsive disorder and related conditions.
    Goodman WK; Ward H; Kablinger A; Murphy T
    J Clin Psychiatry; 1997; 58 Suppl 5():32-49. PubMed ID: 9184625
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Serotonin function in panic disorder: a double blind placebo controlled study with fluvoxamine and ritanserin.
    Den Boer JA; Westenberg HG
    Psychopharmacology (Berl); 1990; 102(1):85-94. PubMed ID: 1697419
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Extended-release fluvoxamine (Luvox CR).
    Med Lett Drugs Ther; 2008 Jun; 50(1289):50-1. PubMed ID: 18583947
    [No Abstract]   [Full Text] [Related]  

  • 30. Treatment outcome of obsessive compulsive disorder with comorbid social phobia.
    Carrasco JL; Hollander E; Schneier FR; Liebowitz MR
    J Clin Psychiatry; 1992 Nov; 53(11):387-91. PubMed ID: 1459968
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of tryptophan depletion on selective serotonin reuptake inhibitor-remitted patients with obsessive compulsive disorder.
    Hood SD; Broyd A; Robinson H; Lee J; Hudaib AR; Hince DA
    J Psychopharmacol; 2017 Dec; 31(12):1615-1623. PubMed ID: 29095069
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of serotonin uptake inhibitors in anxiety disorders; a double-blind comparison of clomipramine and fluvoxamine.
    den Boer JA; Westenberg HG; Kamerbeek WD; Verhoeven WM; Kahn RS
    Int Clin Psychopharmacol; 1987 Jan; 2(1):21-32. PubMed ID: 3117876
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparing the Effects of a Herbal Drug based on
    Noras MR; Soltanifar A; Salari R; Jarahi L; Abrishami MH
    Curr Drug Discov Technol; 2022; 19(5):e240622206368. PubMed ID: 35748547
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Selective serotonin reuptake inhibitors: pharmacologic profiles and potential therapeutic distinctions.
    Finley PR
    Ann Pharmacother; 1994 Dec; 28(12):1359-69. PubMed ID: 7696728
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Spotlight on fluvoxamine in anxiety disorders in children and adolescents.
    Cheer SM; Figgitt DP
    CNS Drugs; 2002; 16(2):139-44. PubMed ID: 11825104
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Neurobiology and pharmacotherapy of social phobia].
    Aouizerate B; Martin-Guehl C; Tignol J
    Encephale; 2004; 30(4):301-13. PubMed ID: 15538306
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Partial role of 5-HT2 and 5-HT3 receptors in the activity of antidepressants in the mouse forced swimming test.
    Redrobe JP; Bourin M
    Eur J Pharmacol; 1997 May; 325(2-3):129-35. PubMed ID: 9163559
    [TBL] [Abstract][Full Text] [Related]  

  • 38. N-acetylcysteine augmentation in serotonin reuptake inhibitor refractory obsessive-compulsive disorder.
    Lafleur DL; Pittenger C; Kelmendi B; Gardner T; Wasylink S; Malison RT; Sanacora G; Krystal JH; Coric V
    Psychopharmacology (Berl); 2006 Jan; 184(2):254-6. PubMed ID: 16374600
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Differential effects of the 5-HT2 receptor antagonist on the anti-immobility effects of noradrenaline and serotonin reuptake inhibitors in the forced swimming test.
    Yamada J; Sugimoto Y
    Brain Res; 2002 Dec; 958(1):161-5. PubMed ID: 12468041
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A comparative examination of a role for serotonin in obsessive compulsive disorder, panic disorder, and anxiety.
    Murphy DL; Pigott TA
    J Clin Psychiatry; 1990 Apr; 51 Suppl():53-8; discussion 59-60. PubMed ID: 2139026
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.